A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Shen, Songjie ^a   Sun, Qiang ^a   Liang, Zhiyong ^a   Cui, Xiaojiang ^b   Ren, Xinyu ^a   Chen, Huan ^c   Zhang, Xiao ^b   Zhou, Yidong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Zhejiang Institute of Microbiology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MICRORNA; MICRORNA 103A 3P; MICRORNA 107; MICRORNA 27B 3P; PROTEIN P53; UNCLASSIFIED DRUG; MIRN103 MICRORNA, HUMAN; MIRN107 MICRORNA, HUMAN; MIRN27 MICRORNA, HUMAN;

ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; PARTIAL MASTECTOMY; PATIENT CODING; PERSONALIZED MEDICINE; PREDICTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; AGED; CARCINOMA, DUCTAL, BREAST; GENETICS; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; SURVIVAL; TRIPLE NEGATIVE BREAST NEOPLASMS;

AGE FACTORS; AGED; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903289152     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100664     Document Type: Article

References (40)

1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
2. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, et al. (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30: 1879-1887.
3. Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL (2008) Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res 14: 4168-4174.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434. (Pubitemid 47219710)
5. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, et al. (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7: e1000279.
6. Hallett RM, Dvorkin-Gheva A, Bane A, Hassell JA (2012) A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep 2: 227.
7. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, et al. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32. (Pubitemid 46120191)
8. Shen S, Sun Q, Zhou Y, Guan J, Mao F, et al. (2013) Analysis of prognostic factors related to triple-negative breast cancer. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery] 51: 1000-1004.
9. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, et al. (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29: 2628-2634.
10. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, et al. (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31: 2783-2790.
11. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, et al. (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119: 551-558.
12. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Metaanalysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65.
13. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158-5165.
14. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, et al. (2010) A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12: R85.
15. Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, et al. (2012) Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One 7: e45831.
16. Negrini M, Calin GA (2008) Breast cancer metastasis: a microRNA story. Breast Cancer Res 10: 203.
17. Le XF, Merchant O, Bast RC, Calin GA (2010) The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron 3: 137-147.
18. Ferracin M, Veronese A, Negrini M (2010) Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 10: 297-308.
19. Yu SL, Chen HY, Yang PC, Chen JJ (2007) Unique MicroRNA signature and clinical outcome of cancers. DNA Cell Biol 26: 283-292.
20. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, et al. (2011) microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71: 5635-5645.
21. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, et al. (2010) A MicroRNA targeting dicer for metastasis control. Cell 141: 1195-1207.
22. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348-2360.
23. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, et al. (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105: 13021-13026.
24. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, et al. (2011) Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 6: e20980.
25. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145. (Pubitemid 350003059)
26. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, et al. (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784-2795.
27. Thomson JM, Parker J, Perou CM, Hammond SM (2004) A custom microarray platform for analysis of microRNA gene expression. Nat Methods 1: 47-53.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
29. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, et al. (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24: 2206-2223.
30. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376. (Pubitemid 351413917)
31. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244. (Pubitemid 46291713)
32. Constantinidou A, Jones RL, Reis-Filho JS (2010) Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther 10: 1197-1213.
33. Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16 Suppl 1: 1-11.
34. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, et al. (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13: 1668-1674. (Pubitemid 47481675)
35. Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, et al. (2008) An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 10: 513-519.
36. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, et al. (2013) Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8: e55910.
37. Svoboda M, Sana J, Redova M, Navratil J, Palacova M, et al. (2012) MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol 7: 31.
38. Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, et al. (2012) High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol 42: 256-263.
39. Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA, et al. (2013) Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer. Cancer Res 73: 2884-2896.
40. Lee JJ, Drakaki A, Iliopoulos D, Struhl K (2012) MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 31: 3818-3825.